Listen to this article
Hikma Pharmaceuticals is topping the FTSE All Share this morning after the company reported better than expected results for 2016.
The generic drug specialist earlier said that a fall in operating profits last year was not as bad as expected, while revenues were a touch better than expectations.
Hikma also slightly raised its dividend for last year and predicted revenue growth of 10 per cent in 2017.
Get alerts on Hikma Pharmaceuticals PLC when a new story is published